WMUK News

Ibrutinib finally approved for WM

Ibrutinib finally approved for WM

28-Sep-2017

Ibrutinib, the BTK inhibitor marketed by Janssen has been approved (subject to a 15 day appeal period) for Waldenstrom patients by NICE to enter the Cancer Drugs Fund to treat relapsed patients and those not suitable for chemo-immunotherapy. Read our 28th September press release below! The roll out of the Rory Morrison Registry Project can now take place nationwide, and your support will be vital to expand the number of data collection hospital centres.

 

Press release 28th September 2017
 
WMUK welcomes the availability of Ibrutinib (Imbruvica™) for relapsed Waldenström’s Macroglobulinemia patients in England through the Cancer Drugs Fund

 

The long awaited publication of the Final Appraisal Document by NICE of Ibrutinib for relapsed Waldenström’s Patients (and those not suitable for conventional chemo immuno therapy), through the Cancer Drugs Fund, will be warmly welcomed both by clinicians treating this rarer blood cancer and by the community of Waldenström’s patients.
It is fitting that this announcement is taking place in September- Blood Cancer Awareness Month. It should be available in England soon after a further 15 day appeal period.

 

Waldenström’s Macroglobulinemia (WM) is a rarer, slow moving, relapsing blood cancer (a type of non Hodgkin Lymphoma) mainly of older people which is treatable, but generally incurable. With modest response rates to conventional chemotherapy and survival rates for patients comparing unfavourably with many EU countries, this is a step change in treatment.
The action of Ibrutinib is unlike chemotherapy in that it is a daily oral treatment of three pills which in many patients will keep the cancer under control for years and allow them to have productive lives. It’s particularly valuable for older patients who cannot tolerate aggressive chemotherapy and in younger patients it may allow them to keep working and have a normal family life.

 

Roger Brown, Chair of WMUK, the joint doctor/patient charity said:
“Ibrutinib approval is a quantum leap for Waldenström’s patients and it is our first targeted treatment. For many patients it will also avoid repeated gruelling chemotherapy. We also welcome NICE’s encouragement of the collection of additional treatment data through the dedicated Rory Morrison Clinical Registry”

 

Dr Shirley D’Sa of University College Hospital, London, WMUK Trustee and Chair of the UK WM Doctors’ Forum said:
“I welcome the good news that Ibrutinib (Imbruvica™) is to be made available through the Cancer Drugs Fund (CDF) in England for relapsed Waldenström’s Macroglobulinemia (WM) patients.
Rarer blood cancers such as WM traditionally rely on hand-me-down treatments from similar blood cancers, and this Bruton’s Tyrosine Kinase inhibitor will be the first new targeted treatment available for WM patients and the first avoiding the use of chemotherapy. Ibrutinib is already widely used in other EU countries and the USA. Both the WMUK charity and the WM Doctors’ Forum have lobbied tirelessly for this to be available and both strongly supported the application to NICE.”
She added:
“During its two-year CDF trial period, it will be vital to capture patient treatment data to support its continued use. To that end, WMUK, with an unrestricted grant from Janssen have set up a network of 11 WM treatment centres to capture treatment data via the Rory Morrison Registry (RMR), and are looking to recruit more UK centres to join soon, so as many patients as possible can contribute their data. “

 

Background Notes
1) Ibrutinib for Relapsed WM was approved by the European Medicines Agency in June 2015. It is already available in many European Countries including Ireland and Greece, and is widely used in the USA, where it was developed and first trialled, starting in 2012.
2) NICE started the Ibrutinib assessment process on 4th December 2015 and took 21 months to complete it.
3) In order to supply complete information on treatment for the CDF to assess its effectiveness at the end of the trial period and facilitate vital research in this rarer disease, WMUK and Janssen UK worked together with consultants to set up treatment data collection using the Rory Morrison Clinical Registry (named in honour of the Radio 4 announcer, who died of WM) and data collection will commence at 11 major hospital centres treating WM. More centres are being encouraged to join in and support this massive effort for a rarer disease. Some 400 patients are already enrolled in the Registry.
4) Some 300-400 UK patients are diagnosed with WM each year, and there are roughly 4000 in the UK community.
5) In a snap survey by WMUK, to which 220 WM patients responded, patients were asked if they had concerns with their data being captured in the WM clinical registry. Not a single patient raised concerns. It is clear that in rarer diseases, patients are extremely positive about using their data to further research.
6) WMUK has worked extensively with NICE and Janssen UK to secure approval for Ibrutinib over the past two years, and we were strongly supported by the major blood cancer organisations including the Lymphoma Association, Bloodwise, Leukaemia Care, the International Waldenström’s Macroglobulinemia Foundation (IWMF, USA) and Lymphoma Canada.
7) Notable historic sufferers of WM include President Pompidou of France and the Shah of Iran

 



News and Event - Events
 

 

DEPARTMENT OF HEALTH, NORTHERN IRELAND ANNOUNCES EASIER ACCESS TO TREATMENT FOR CANCER PATIENTS

DEPARTMENT OF HEALTH, NORTHERN IRELAND ANNOUNCES EASIER ACCESS TO TREATMENT FOR CANCER PATIENTS

11-Oct-2018
Department of Health, Northern Ireland issued a press release outlining plans for 'Improved Access to New Drugs' to cancer patients in Northern Ireland and announced plans to introduce changes to ensure that all patients have the same access to cancer drugs and treatment options as the rest of the UK.

Ibrutinib finally approved for WM

Ibrutinib finally approved for WM

28-Sep-2017
Ibrutinib, the BTK inhibitor marketed by Janssen has been approved (subject to a 15 day appeal period) for Waldenstrom patients by NICE to enter the Cancer Drugs Fund to treat relapsed patients and those not suitable for chemo-immunotherapy. Read our 28th September press release below! The roll out of the Rory Morrison Registry Project can now take place nationwide, and your support will be vital to expand the number of data collection hospital centres.

WMUK helps make Blood Cancer Visible

WMUK helps make Blood Cancer Visible

14-Sep-2017
8 WMUK volunteers- with our Patron Charlotte Green leading the event- volunteered to be part of the MBCV in September at Paternoster Square, next to St.Paul's Cathedral. This consisted of 104 installations representing the first names and heights of the number of people diagnosed each day with blood cancer, created by artist Paul Cocksedge. Each installation had the patient's story. Watch the video! Pictures below!

Seb's Video Tale- newly diagnosed

Seb's Video Tale- newly diagnosed

07-Jul-2017
Seb's inspirational talk about being diagnosed is compulsive viewing for the younger diagnosed patient.

WMUK Guide to WM updated

WMUK Guide to WM updated

01-May-2017
WMUK's popular guide to WM, authored by WMUK Trustee Dr Shirley D'Sa of UCLH has been updated and can be viewed/downloaded as a PDF.

WMUK joins in letter to PM on healthcare rationing

WMUK joins in letter to PM on healthcare rationing

19-Feb-2017
WMUK, a member of the Specialised Healthcare Alliance, has signed a letter to Theresa May calling for fair treatment for patients with rare and complex conditions. The Observer and Guardian carried the story on Sunday 19th February.

Transplants in WM reinstated!

Transplants in WM reinstated!

04-Dec-2016
NHS England announced today that stem cell transplants in WM would be funded, ending months of speculation when the proposed policy was held back in August pending the court decision on PrEP. Thanks go to all our community, supporters and members of fellow blood cancer charities in raising the issues of proper treatment for this disease, particularly in signing a 12,000+ strong petition in Parliament.
Particular thanks to Harriet (pictured) and Sandra who stood up and were counted,driving the campaign. Both have now had their transplants and are back home recovering.

Ibrutinib approved for CLL- can WM be far behind?

Ibrutinib approved for CLL- can WM be far behind?

25-Nov-2016
NICE has announced that Ibrutinib (Imbruvica® ) is to be approved for use in relapsed Chronic Lymphocytic Leukaemia. This removes it from the Cancer Drugs fund into routine commissioning. Ibrutinib in relapsed WM and Mantle Cell Leukaemia both await NICE decisions. In relapsed WM (and those not suitable for conventional chemo-immunotherapy), Janssen have applied to put the drug into the new Cancer Drugs Fund.
You can download the Janssen press release which mentions WM.

Make Blood Cancer Visible (MBCV) - 2018 Campaign

Make Blood Cancer Visible (MBCV) - 2018 Campaign

03-Oct-2018
JOURNEY OF THE MBCV 2018 ROADSHOW

Heroic School Bake for Waldenstrom Research

Heroic School Bake for Waldenstrom Research

19-Jul-2017
8 Year 4 pupils at Holy Cross Primary Academy, Hucknall, took on a cake baking challenge for their fete to raise money for Waldenstrom Research, as they were so concerned when one of their relatives was diagnosed with WM

Village Quiz raises £7,000 for WMUK

Village Quiz raises £7,000 for WMUK

30-Dec-2015
The Peire family aided by their friends at High5 Events raised a fantastic £7,000 in their village hall quiz at Barton-Le-Clay, Bedfordshire

WMUK & Blood Cancers Alliance lobby health minister

WMUK & Blood Cancers Alliance lobby health minister

04-Nov-2015
WMUK joined the Blood Cancers Alliance to fight for better treatment for blood cancer patients. Read the Alliance open letter to Rt. Hon. Jeremy Hunt MP, Secretary of State for Health- then sign the petition and tell your friends!

Laugh4Rory Now tops £8K!

Laugh4Rory Now tops £8K!

01-May-2015
Rory's BBC Radio colleagues Susan Calman, Jeremy Hardy Isy Suttie, Elis James,Andy Hamilton and John Finnemore raised over £8,000 for the Rory Morrison Cinical Registry at RADA

Run4Rory- £4000+ raised for the WM Registry

Run4Rory- £4000+ raised for the WM Registry

03-Aug-2014
Rosie Durham ran in the Womens' Running 10k race in Bristol on 2nd August and has raised over £4000 to date for the Rory Morrison Clinical Registry. See the WMUK page at https://www.justgiving.com/wmuk for more ideas about sponsored events.

Newsletter Number 3, March 2014 available now!

Newsletter Number 3, March 2014 available now!

15-Mar-2014
Download or read the new newsletter

New Guide to WM published by WMUK

New Guide to WM published by WMUK

25-Mar-2014
This new guide is written for WMUK by Dr Shirley D'Sa of University College Hospital London

THREE INTERESTING DANA FARBER ARTICLES ON WM TREATMENT

THREE INTERESTING DANA FARBER ARTICLES ON WM TREATMENT

18-Dec-2011

TRIAL SHOWS RITUXIMAB SUPERIOR TO WATCH AND WAIT

TRIAL SHOWS RITUXIMAB SUPERIOR TO WATCH AND WAIT

01-May-2012

WMUK APPOINTS RUPINDER BANCIL AS AN ADMINISTRATION OFFICER

WMUK APPOINTS RUPINDER BANCIL AS AN ADMINISTRATION OFFICER

12-Oct-2018
Rupinder has become part of the WM family in the capacity of an Administrator to deal with day-to-day tasks of the charity and to support the Trustees in their work.

WMUK APPOINTS SANDRA INGRAM AS A TRUSTEE AND CHARITY TREASURER

WMUK APPOINTS SANDRA INGRAM AS A TRUSTEE AND CHARITY TREASURER

11-Oct-2018
WMUK continues to grow with our newest addition, Sandra Ingram as our Patient Trustee and Treasurer

WMUK WELCOMES ERIC LOW AS AN INVALUABLE ADDITION TO OUR BOARD OF TRUSTEES

WMUK WELCOMES ERIC LOW AS AN INVALUABLE ADDITION TO OUR BOARD OF TRUSTEES

12-Oct-2018
Eric Low, former Chief Executuve and founder of Myeloma UK, has joined WMUK Board of Trustees. Eric brings with him invaluable knowledge and experience to carry forward the vision of WMUK.